DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Baird Upgrades Pieris Pharmaceuticals to Outperform, Announces $5 Price Target

Baird analyst Madhu Kumar upgrades Pieris Pharmaceuticals (NASDAQ:PIRS) from Neutral to Outperform and announces $5 price target.

Benzinga · 03/13/2020 14:27

Baird analyst Madhu Kumar upgrades Pieris Pharmaceuticals (NASDAQ:PIRS) from Neutral to Outperform and announces $5 price target.